254 related articles for article (PubMed ID: 26690867)
21. Doxorubicin-loaded functionalized selenium nanoparticles for enhanced antitumor efficacy in cervical carcinoma therapy.
Xia Y; Xiao M; Zhao M; Xu T; Guo M; Wang C; Li Y; Zhu B; Liu H
Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110100. PubMed ID: 31753388
[TBL] [Abstract][Full Text] [Related]
22. Decapeptide functionalized targeted mesoporous silica nanoparticles with doxorubicin exhibit enhanced apoptotic effect in breast and prostate cancer cells.
Tambe P; Kumar P; Paknikar KM; Gajbhiye V
Int J Nanomedicine; 2018; 13():7669-7680. PubMed ID: 30538451
[TBL] [Abstract][Full Text] [Related]
23. α-Bisabolol Attenuates Doxorubicin Induced Renal Toxicity by Modulating NF-κB/MAPK Signaling and Caspase-Dependent Apoptosis in Rats.
Arunachalam S; Nagoor Meeran MF; Azimullah S; Jha NK; Saraswathiamma D; Subramanya S; Albawardi A; Ojha S
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142441
[TBL] [Abstract][Full Text] [Related]
24. Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates.
Cai S; Alhowyan AA; Yang Q; Forrest WC; Shnayder Y; Forrest ML
J Drug Target; 2014 Aug; 22(7):648-57. PubMed ID: 24892741
[TBL] [Abstract][Full Text] [Related]
25. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin.
Yadav AK; Mishra P; Jain S; Mishra P; Mishra AK; Agrawal GP
J Drug Target; 2008 Jul; 16(6):464-78. PubMed ID: 18604659
[TBL] [Abstract][Full Text] [Related]
26. CD-340 functionalized doxorubicin-loaded nanoparticle induces apoptosis and reduces tumor volume along with drug-related cardiotoxicity in mice.
Mondal L; Mukherjee B; Das K; Bhattacharya S; Dutta D; Chakraborty S; Pal MM; Gaonkar RH; Debnath MC
Int J Nanomedicine; 2019; 14():8073-8094. PubMed ID: 31632019
[TBL] [Abstract][Full Text] [Related]
27. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
28. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
[TBL] [Abstract][Full Text] [Related]
29. Hyaluronic acid-coated pH sensitive poly (β-amino ester) nanoparticles for co-delivery of embelin and TRAIL plasmid for triple negative breast cancer treatment.
Xu Y; Liu D; Hu J; Ding P; Chen M
Int J Pharm; 2020 Jan; 573():118637. PubMed ID: 31550511
[TBL] [Abstract][Full Text] [Related]
30. Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy.
Liu Q; Li J; Pu G; Zhang F; Liu H; Zhang Y
Drug Deliv; 2016 May; 23(4):1364-8. PubMed ID: 25874959
[TBL] [Abstract][Full Text] [Related]
31. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe
Fang Z; Li X; Xu Z; Du F; Wang W; Shi R; Gao D
Int J Nanomedicine; 2019; 14():5785-5797. PubMed ID: 31440047
[No Abstract] [Full Text] [Related]
32. Blocking Interleukin-4 Receptor α Using Polyethylene Glycol Functionalized Superparamagnetic Iron Oxide Nanocarriers to Inhibit Breast Cancer Cell Proliferation.
Shaik AP; Shaik AS; Majwal AA; Faraj AA
Cancer Res Treat; 2017 Apr; 49(2):322-329. PubMed ID: 27456946
[TBL] [Abstract][Full Text] [Related]
33. Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity.
Alimoradi H; Greish K; Barzegar-Fallah A; Alshaibani L; Pittalà V
Int J Nanomedicine; 2018; 13():7771-7787. PubMed ID: 30538458
[TBL] [Abstract][Full Text] [Related]
34. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.
Alinejad V; Hossein Somi M; Baradaran B; Akbarzadeh P; Atyabi F; Kazerooni H; Samadi Kafil H; Aghebati Maleki L; Siah Mansouri H; Yousefi M
Biomed Pharmacother; 2016 Oct; 83():229-240. PubMed ID: 27372407
[TBL] [Abstract][Full Text] [Related]
35. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
36. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
37. pH- and GSH-Sensitive Hyaluronic Acid-MP Conjugate Micelles for Intracellular Delivery of Doxorubicin to Colon Cancer Cells and Cancer Stem Cells.
Debele TA; Yu LY; Yang CS; Shen YA; Lo CL
Biomacromolecules; 2018 Sep; 19(9):3725-3737. PubMed ID: 30044910
[TBL] [Abstract][Full Text] [Related]
38. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
[TBL] [Abstract][Full Text] [Related]
39. Water-Responsive Hybrid Nanoparticles Codelivering ICG and DOX Effectively Treat Breast Cancer via Hyperthermia-aided DOX Functionality and Drug Penetration.
Liu X; Wang C; Ma H; Yu F; Hu F; Yuan H
Adv Healthc Mater; 2019 Apr; 8(8):e1801486. PubMed ID: 30856296
[TBL] [Abstract][Full Text] [Related]
40. Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization.
Wu YW; Lee DY; Lu YL; Delila L; Nebie O; Barro L; Changou CA; Lu LS; Goubran H; Burnouf T
Platelets; 2023 Dec; 34(1):2237134. PubMed ID: 37580876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
